logo-loader
viewOncimmune

Oncimmune Holdings draws down final tranche of IPF facility

The new funds will be used to bankroll its commercial push based around its EarlyCDT technology, which is used to detect cancer

Oncimmune -
The company is on the commercial growth trail

Oncimmune Holdings PLC (LON:ONC) has drawn down €3.5mln from its credit facility with IPF Management.

It is the second and final tranche from the facility after the diagnostics specialist banked €5mln on September 20.

The new funds will be used to bankroll its commercial push based around its EarlyCDT technology, which is used to detect cancer.

Last week (October 31), the company said it had “minimum sales commitments” of £42mln as it provided an update on its financial and operational progress.

Quick facts: Oncimmune

Price: 37.3 GBX

AIM:ONC
Market: AIM
Market Cap: £23.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and...

on 1/11/19

2 min read